Drug Type Small molecule drug |
Synonyms UK5099 |
Target |
Action inhibitors |
Mechanism MPC1 inhibitors(mitochondrial pyruvate carrier 1 inhibitors), MPC2 inhibitors(mitochondrial pyruvate carrier 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H12N2O2 |
InChIKeyBIZNHCWFGNKBBZ-UHFFFAOYSA-N |
CAS Registry56396-35-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Preclinical | United States | 05 Mar 2025 | |
Neurodegenerative Diseases | Preclinical | United States | 05 Mar 2025 | |
Nonalcoholic Steatohepatitis | Preclinical | United States | 05 Mar 2025 | |
Non-Small Cell Lung Cancer | Discovery | United States | 19 Jun 2024 |